Resolution criteria

This market resolves YES if OKYO Pharma (OKYO) has a larger percentage gain than IN8bio (INAB) from market close on November 21, 2025 to market open on November 24, 2025. The percentage gain is calculated as: ((Price at market open Nov 24 - Price at market close Nov 21) / Price at market close Nov 21) × 100.

Resolution will be determined using official closing prices from NASDAQ for November 21 and official opening prices from NASDAQ for November 24. Sources: NASDAQ OKYO and NASDAQ INAB.

Background

OKYO Pharma is a clinical-stage biopharmaceutical company developing innovative therapies for neuropathic corneal pain and dry eye disease, with a Phase 2 trial of urcosimod recently completed. On November 21, 2025, OKYO announced that its Executive Chairman acquired 82,018 additional shares, bringing his total holding to 10,464,695 shares. OKYO's CEO will present at the Ophthalmology Innovation Summit (OIS) XV on November 22, 2025, from 8:30-9:30 AM PT.

IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. IN8bio reported Q3 2025 results on November 6, 2025, presenting new preclinical data on INB-619 showing efficacy equivalent to FDA-approved compounds with minimal cytokine release.

Considerations

Both stocks are micro-cap biotech companies with high volatility. OKYO traded between $2.08 and $2.55 on November 21, while INAB ranged between $2.11 and $2.31 with a previous close of $2.34. The three-day window is short and subject to market sentiment shifts, clinical trial announcements, or broader biotech sector movements. OKYO's CEO presentation on November 22 could influence trading, though the impact is uncertain.